Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 4 | SFE2002 | Next issue

193rd Meeting of the Society for Endocrinology and Society for Endocrinology joint Endocrinology and Diabetes Day

Oral Communications

Growth regulation and development

ea0004oc1 | Growth regulation and development | SFE2002

Reduced maternal nutrition in late gestation acts to decrease prolactin receptor abundance in adipose tissue and later fat deposition

Korur N , Pearce S , Dandrea J , Ingleton P , Symonds M , Stephenson T

Introduction: Mice in which the prolactin receptor (PRLR) gene is knocked out have reduced adipose tissue in later life. Abundance of the PRLR is greatest in adipose tissue at birth and is reduced following placental restriction. The present study investigated the impact of maternal nutrient restriction over the final two months of gestation on PRLR abundance in developing lambs.Methods: Eighteen multiparous twin bearing ewes were entered into the study,...

ea0004oc2 | Growth regulation and development | SFE2002

The effect of chronic umbilical cord occlusion on mitochondrial protein abundance in the late gestation ovine fetus

Gnanalingham M , Mostyn A , Giussani D , Stephenson T , Symonds M , Gardner D

Introduction: Umbilical cord occlusion (UO) sufficient to restrict fetal blood supply by 30 percent results in a range of fetal endocrine adaptations including increased fetal plasma cortisol. The extent to which this may promote premature maturation of fetal organs and tissues is not known. This study aimed to determine if UO results in premature maturation of mitochondria within fetal adipose tissue.Methods: Nine ewes were entered into the study, which...

ea0004oc3 | Growth regulation and development | SFE2002

Influence of genotype on the endocrine and metabolic control of uncoupling protein (UCP)-2 during the first week of life in neonatal piglets

Mostyn A , Litten J , Perkins K , Symonds M , Clarke L

It is well established that neonatal mortality is greater in the leaner commercial (C) porcine genotypes compared to the ancient Meishan (M) breed, which has a higher percentage of body fat. Piglets do not express UCP1, responsible for heat production in neonatal mammals, although they do express UCP2. The aim of this study was to investigate the endocrine and metabolic control of UCP2 expression between the C and M genotypes.Piglets from 15 C and 15 M l...

ea0004oc4 | Growth regulation and development | SFE2002

Somatostatin inhibits the release of Ghrelin in normal subjects

Tan T , Levy M , Skinner V , Beaumont N , Srai K , Goadsby P , Bouloux P , Vanderpump M

Ghrelin is a 28 amino acid n-octanoylated peptide which is the natural agonist for the growth hormone secretagogue receptor and which potently stimulates GH release in vivo (1). We studied the effects of a somatostatin infusion on Ghrelin release in normal subjects.STUDY PROTOCOLFour females and five males, 25-40 years of age, body mass index < 28 kg per m2 were studied. Local ethics committee permission was obtained for ...

ea0004oc5 | Growth regulation and development | SFE2002

27 YEARS ON - IMPROVED FINAL HEIGHT WITH GROWTH HORMONE THERAPY AFTER IRRADIATION FOR CHILDHOOD BRAIN TUMOURS REFLECTING EVOLVING ENDOCRINE PRACTICE

Stoeter R , Gleeson H , Ogilvy-Stuart A , Shalet S

Final height outcome is important in survivors of childhood brain tumours. Growth hormone replacement is indicated in those found to be GH deficient (GHD). More recently, GnRH analogues (GnRHa) have been introduced to delay early or rapidly progressing puberty. Studies to final height are important to determine the effectiveness of growth promoting strategies.SUBJECTS & METHODS Final height results in children receiving GH replacement for radiation i...

ea0004oc6 | Growth regulation and development | SFE2002

Pulse Wave Velocity and Blood Pressure are reduced by 6 months of Growth Hormone Therapy in Adult Growth Hormone Deficient Patients

McCallum R , Petrie J , Dominiczak A , Connell J

BackgroundPatients with Growth Hormone Deficiency (GHD) are known to have an excess risk of vascular disease. Previous work has shown an increase in their arterial stiffness. The effect of GH on blood pressure is still unclear.Materials and Methods16 patients with GHD (6 males) and no history of existing vascular disease or hypertension, between the ages of 18 and 65 were recruited (mean 45.4 plus/minus 3.5 y...

ea0004oc7 | Growth regulation and development | SFE2002

DOES GROWTH HORMONE REDUCE SENSORINEURAL DEAFNESS IN ADULTS WITH TURNER SYNDROME?

Ostberg J , Beckman A , Cadge B , Conway G

IntroductionWomen with Turner Syndrome have an increased prevalence of hearing loss. Conductive hearing loss (CHL) is thought to be caused by craniofacial abnormalities or defective mucociliary transport resulting in impaired middle ear ventilation, increased otitis media and tympanic perforations. Sensorineural hearing loss (SNHL) progresses with age, possibly due to premature aging. An adult population was assessed for the impact of childhood treatment...

ea0004oc8 | Growth regulation and development | SFE2002

HOW TO OPTIMISE PEGVISOMANT TREATMENT OF ACROMEGALY SAFELY?

Mukherjee A , Trainer P , Monson J , Shalet S

Objective: To identify a range of IGF-I values representative of growth hormone deficiency (GHD), which could be utilised to reduce the risk of 'functional' GHD in Pegvisomant treated acromegaly.Method: We analysed centrally measured IGF-I data from the KIMS European GHD database. We stratified this cohort into six gender based, age ranges and assessed IGF-I and IGF-I standard deviation scores (SDS).Results: Baseline measurements f...